Pulmonary Fibrosis

A study in Japan found that antifibrotic treatment rates for patients with idiopathic pulmonary fibrosis (IPF) varied by medical facility, with higher treatment rates observed in referral hospitals than in general hospitals or clinics.

The increase in the global burden of interstitial lung disease (ILD) and pulmonary sarcoidosis had the greatest impact on countries with a high sociodemographic index.

This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options for patients with idiopathic pulmonary fibrosis (IPF).

Maria L. Padilla, MD, Icahn School of Medicine at Mount Sinai, previews that experts will discuss critical management strategies for interstitial lung disease and idiopathic pulmonary fibrosis, including the latest diagnosis and treatment protocol advancements, at Advances in Pulmonary Medicine 2024.

Despite proven benefits, referrals to pulmonary rehabilitation and palliative care for patients with idiopathic pulmonary fibrosis (IPF) in England remain significantly lower than for other respiratory conditions.

Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.

Two posters presented at the CHEST 2024 annual meeting highlighted the importance of addressing socioeconomic disparities and identifying clinical predictors to improve outcomes and survival rates among patients with idiopathic pulmonary fibrosis (IPF).

Two posters presented at CHEST 2024 revealed significant racial and ethnic disparities in the hospitalization and treatment of patients with idiopathic pulmonary fibrosis (IPF), with Black patients hospitalized at younger ages but less likely to receive antifibrotic medications than White patients.

The positive phase 3 results showed improved lung function with nerandomilast vs placebo at 52 weeks in idiopathic pulmonary fibrosis (IPF).

Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic cough in patients with idiopathic pulmonary fibrosis and other interstitial lung diseases.

Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).

Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.

A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and progressive pulmonary fibrosis (PPF).

New findings point to a 6% decrease in mortality risk for each unit increase in body mass index (BMI).

Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.

The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.

Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast.

An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.

Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.

Dr Nathan provides his final thoughts regarding IPF management.

Dr Nathan discusses the trajectory of IPF management.

Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.

Dr Nathan highlights the role of PDE4B inhibitors in IPF management.

Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.

While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.

Patients with fibrosing interstitial lung disease (ILD) who began supplemental oxygen therapy had triple the per patient per month ILD-related health care costs compared with those who did not.

Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.